<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983928</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-Ib-11</org_study_id>
    <nct_id>NCT03983928</nct_id>
  </id_info>
  <brief_title>Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer</brief_title>
  <official_title>A Phase Ib, Open-label, Single Center, Non-randomized Study for Safety and Efficacy of TQB2450 Combined With Anlotinib in Subjects With Advanced Mutation Positive Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single center, non-randomized, phase Ib trial to evaluate safety and&#xD;
      efficacy of TQB2450 injection combined with anlotinib in patients with advanced mutation&#xD;
      positive non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate （ORR）</measure>
    <time_frame>up to approximately 12 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to approximately 12 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 15 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to approximately 12 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450 Combined with Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450 Combined with Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>a multi-target receptor tyrosine kinase inhibitor</description>
    <arm_group_label>TQB2450 Combined with Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understood and signed an informed consent form.&#xD;
&#xD;
          2. 18 years and older.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life&#xD;
             expectancy≥ 12 weeks.&#xD;
&#xD;
          4. Histologically or cytologically confirmed mutation positive non-small cell lung cancer&#xD;
             according to 8th International Association for the Study of Lung Cancer (IASLC)&#xD;
             edition.&#xD;
&#xD;
          5. Has measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             version 1.1.&#xD;
&#xD;
          6. Adequate organ system function, defined as follows:&#xD;
&#xD;
               1. absolute neutrophil count (ANC) ≥ 1.5×10^9/L, platelets (PLT) ≥ 100×10^9/L,&#xD;
                  hemoglobin (Hb)≥ 90g /L;&#xD;
&#xD;
               2. total bilirubin (TBIL) ≤ 1.5×ULN；alanine transaminase (ALT) and aspartate&#xD;
                  aminotransferase (AST) ≤ 3.0 × ULN (without liver metastasis) or ≤ 5.0 × ULN&#xD;
                  (with liver metastasis), Creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50&#xD;
                  ml/min;&#xD;
&#xD;
               3. Urine protein &lt; ++，or urine protein ≥ ++ concomitant with content of 24-hour&#xD;
                  urinary protein &lt;1.0 g;&#xD;
&#xD;
               4. international normalized ratio (INR) ≤ 1.5×ULN, activated partial thromboplastin&#xD;
                  time (APTT) ≤ 1.5×ULN;&#xD;
&#xD;
               5. left ventricular ejection fraction (LVEF) ≥ 50%;&#xD;
&#xD;
          7. Male or female subjects should agree to use an adequate method of contraception&#xD;
             starting with the first dose of study therapy through 6 months after the last dose of&#xD;
             study (such as intrauterine devices , contraceptives or condoms) ; No pregnant or&#xD;
             breastfeeding women, and a negative pregnancy test are received within 7 days before&#xD;
             the randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has diagnosed and/or treated additional malignancy within 5 years prior to&#xD;
             randomization except of cured in situ carcinoma of the cervix, non-melanoma skin&#xD;
             cancer and superficial bladder carcinoma.&#xD;
&#xD;
          2. Has severe hypersensitivity reactions after taking other monoclonal antibodies.&#xD;
&#xD;
          3. Has hypersensitivity reactions after taking anlotinib.&#xD;
&#xD;
          4. Has prior therapy with anlotinib, anti-programmed cell death (PD)-1, anti-PD-L1 or&#xD;
             other immunotherapy against PD-1/PD-L1.&#xD;
&#xD;
          5. Has any active autoimmune disease or history of autoimmune disease, such as autoimmune&#xD;
             hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis, asthma patients&#xD;
             who need bronchiectasis for medical intervention; Subjects with the vitiligo without&#xD;
             systemic treatment, psoriasis, alopecia, well-controlled type I diabetes mellitus,&#xD;
             hypothyroidism stable on hormone replacement will not be excluded from this study.&#xD;
&#xD;
          6. Has multiple factors affecting oral medication, such as inability to swallow,&#xD;
             post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.&#xD;
&#xD;
          7. Has clinical significance of thyroid dysfunctions within 6 months prior to enrollment,&#xD;
             and even though medical therapy, thyroid function can not return to normal or no&#xD;
             clinical significance.&#xD;
&#xD;
          8. Has central nervous system (CNS) metastases without local therapy of lesion.&#xD;
&#xD;
          9. Radiograph (within 28 days before enrollment) showed that the tumor surrounded&#xD;
             important blood vessels, and the investigators determined that entering the study&#xD;
             would cause bleeding risk.&#xD;
&#xD;
         10. Hemoptysis (defined as coughing out or spitting out ≥ 1 teaspoon of blood or small&#xD;
             blood clots or hemoptysis without sputum) within 28 days before enrollment , not&#xD;
             including bloody sputum.&#xD;
&#xD;
         11. Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable&#xD;
             local hormones (dosage &gt; 10 mg/day prednisone or other therapeutic hormones) is&#xD;
             required for the purpose of immunosuppression, and is still in use for 2 weeks after&#xD;
             the first administration.&#xD;
&#xD;
         12. Has any of the following severe acute complications:&#xD;
&#xD;
               1. Unstable angina and/or congestive heart failure or vascular disease requiring&#xD;
                  hospitalization within 12 months, or other cardiac impairments determined by the&#xD;
                  investigator, which may affect the evaluation of drug safety; Myocardial&#xD;
                  infarction or ischemia with ST elevation ≥ 2 mm indicated by electrocardiogram&#xD;
                  (ECG);&#xD;
&#xD;
               2. Has pulmonary infections and/or acute bacterial or fungal infections requiring&#xD;
                  intravenous antibiotic therapy;&#xD;
&#xD;
               3. Has clinical jaundice caused by liver dysfunction;&#xD;
&#xD;
         13. Virological test indicates one of the following items before enrollment:&#xD;
&#xD;
               1. HBsAg positive and HBV DNA ≥ 1 × 10^3 copies/mL;&#xD;
&#xD;
               2. Anti-HCV positive and HCV virus titer detection value exceeds the upper limit of&#xD;
                  normal value;&#xD;
&#xD;
               3. HIV positive;&#xD;
&#xD;
         14. Has participation in an anti-tumor clinical trial within 28 days prior to the first&#xD;
             administration.&#xD;
&#xD;
         15. Has serious affecting safety or treatment compliance concomitant diseases, according&#xD;
             to the investigator's judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Zhang</last_name>
    <phone>020-87343458</phone>
    <email>zhangli@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
      <phone>020-87343458</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

